The Tpr-Met oncoprotein, which is a member of a family of tyrosine kinase oncoproteins generated following genomic rearrangement, consists of the catalytic kinase domain of the hepatocyte growth factor/scatter factor receptor tyrosine kinase (Met) fused downstream from sequences encoded by the tpr gene. We have previously demonstrated that a single tyrosine residue in the carboxyl terminus, Tyr 489 , is highly phosphorylated and is essential for efficient transformation of Fr3T3 fibroblasts by Tpr-Met and for the association of Tpr-Met with the Grb2 adaptor protein and phosphatidylinositol 3-kinase. We show here that Tyr 489 is also required for association of Tpr-Met with phospholipase C␥ and the tyrosine phosphatase, SHPTP2/Syp. To distinguish which of these substrates are required for cell transfor-
The receptor for hepatocyte growth factor/scatter factor, the Met receptor tyrosine kinase, was originally identified as an oncogene, tpr-met (1, 2) . tpr-met, which belongs to a family of receptor tyrosine kinase-derived oncogenes generated following genomic rearrangement, consists of the cytoplasmic tyrosine kinase domain of the Met receptor fused downstream from sequences encoded by the tpr gene (3) . In addition to Tpr-Met, this family includes chimeric oncoproteins derived from the nerve growth factor receptor (Trk) (4, 5) and Ret (6 -9) . The Tpr portion of Tpr-Met encodes a leucine zipper motif, which mediates dimerization of Tpr-Met (10) . This event is essential for the phosphorylation and constitutive kinase activity of the Tpr-Met oncoprotein and for transformation of Fr3T3 fibroblasts by Tpr-Met (10) . Many of the unrelated amino-terminal portions of the nerve growth factor and Ret receptor tyrosine kinase oncoproteins also contain protein oligomerization motifs (10) . We have proposed that protein dimerization mimics kinase activation of the full-length receptors following ligand binding and that this is a general mechanism for oncogenic activation of this family of receptor tyrosine kinase-derived oncoproteins in human tumors (3) .
The Tpr-Met oncoprotein and many other receptor tyrosine kinase oncoproteins activated by gene rearrangements are no longer expressed at the cell surface, but instead appear to be localized to the cytoplasm (10, 11) . Thus, it is unclear whether they activate the same signaling pathways utilized by their full-length transmembrane receptor counterparts. Activation of the Met receptor by its ligand, hepatocyte growth factor/scatter factor (12, 13) , increases the association, activation, and/or phosphorylation of many signaling molecules including Src, MAP kinase, phospholipase C␥ (PLC␥), 1 Grb2 (14 -18), p120GAP (14, 16) , phosphatidylinositol 3Ј kinase (PI3-kinase) (19) , p125FAK (20) , S6 kinase (21) , and Shc (22) .
To investigate which signal transduction pathways are activated by the Tpr-Met oncoprotein and to identify which of these are important for cell transformation, we have initiated a structure-function analysis of the Tpr-Met oncoprotein. We have shown that a single tyrosine residue in the carboxyl terminus of Tpr-Met (Tyr 489 ) is essential for efficient transformation of Fr3T3 fibroblasts (23) . A Tpr-Met Y489F mutant transforms cells at 20% the efficiency of the wild-type Tpr-Met protein (18, 23) . Although mutation of this residue to a conserved phenylalanine residue does not alter the exogenous kinase activity, the Y489F mutant protein is impaired in its ability to bind to and activate PI3-kinase in vivo and fails to associate with the Grb2 adaptor protein (23) . The Y489F mutant, however, retains the ability to induce phosphorylation of the Shc adaptor protein and the subsequent association with Grb2. However, it was unclear whether the impaired transforming activity of the Y489F mutant was due to the loss of PI3-kinase activity, direct Grb2 association, or other as yet uncharacterized signaling pathways.
In the present study we have further dissected signaling pathways required for transformation of Fr3T3 fibroblasts by the Tpr-Met oncoprotein. Our data indicate that activation of pathways downstream of Shc and Grb2 are essential for transformation of Fr3T3 fibroblasts by the Tpr-Met oncoprotein, whereas pathways downstream from PI3-kinase, PLC␥, and SHPTP2/Syp are insufficient for transformation.
MATERIALS AND METHODS

Mutagenesis-Mutation of Tyr
489 to Phe was described previously (23) as was the generation of the Y482F,and Y482/489F mutations (34) . To generate the N491H Tpr-Met mutant, the protocol of Deng and Nickoloff was followed (24) utilizing the mutagenesis primer: 5Ј-GT-GAACGCTACATATGTGCACGTAAAATGT-3Ј. The conversion of an A to C (underlined) resulted in the conversion of Asn at position 491 to His in the final Tpr-Met mutant product. A secondary mutation of a T to an A (also underlined), which does not alter the protein sequence, was included for purposes of mutagenesis. The mutagenesis was carried out on the 1298-base pair SpeI fragment from Tpr-Met cloned into Bluescript II KSϩ. The final 1298-base pair product was cut with SpeI and substituted back into the tpr-met gene, which lacked the wild-type SpeI fragment. That the sequence of the mutations were correct and the remainder of the gene unchanged was confirmed by nucleotide sequence analysis.
Cell Lines and Tissue Culture-All cell lines were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (Life Technologies, Inc.) and antibiotics. Cell lines expressing either wild-type or mutant forms of Tpr-Met were generated by ecotropic retroviral infection of parental Fischer rat 3T3 (Fr3T3) cells as described previously (25) . Ecotropic retrovirus was produced following transient cotransfection into COS-1 cells of the pLXSN retrovirus vector containing the tpr-met gene with the pSV-Y-E-MLV plasmid, which encodes the retroviral packaging proteins (26) . Medium from the COS-1 cells, which contained packaged virus at approximately 5 ϫ 10 3 plaque forming units/ml, was utilized to infect Fr3T3 cells. Following infection, Fr3T3 cells were subcultured 1:4 into 100-mm dishes. To compare virus titre versus transforming efficiency, two dishes of infected cells were selected in G418, whereas two dishes were maintained at confluence and screened for focus formation 10 -24 days later. Foci and G418-resistant colonies were picked and expanded into cell lines. The ability of stable cell lines expressing either wild-type or mutant forms of Tpr-Met to overgrow a monolayer of Fr3T3 cells was evaluated as described previously (27) .
Antibodies-Antibodies that recognize Tpr-Met were generated against a carboxyl-terminal peptide of the Tpr-Met protein (25) . AntiShc antibody was provided by Dr. John Bergeron. Antibodies to Grb2 were provided by Dr. Mike Moran or purchased from Santa Cruz Biotechnology (Santa Cruz, California). Antibodies that recognize PLC␥ were provided by Dr. Tony Pawson or purchased from Upstate Biotechnology Inc. (Lake Placid, New York). Anti-phosphotyrosine antibody PY20, which was used to immunoprecipitate tyrosine phosphorylated proteins, was purchased from Transduction Laboratories (Lexington, Kentucky). For anti-phosphotyrosine immunoblotting recombinant horseradish peroxidase-conjugated antiphosphotyrosine Fab fragment, RC20H, also purchased from Transduction Laboratories, was utilized.
Cell Lysates, Immunoprecipitation, and Western Blotting-Confluent monolayers of Fr3T3 cells starved in Dulbecco's modified Eagle's medium, 0.1% fetal bovine serum for 24 h were washed twice in ice-cold phosphate-buffered saline and harvested in lysis buffer containing 0.5% Triton X-100, 50 mM HEPES, pH 8.0, 150 mM NaCl, 10% glycerol, 2 mM EGTA, 1.5 mM MgCl 2 , 10 g aprotinin/ml, 10 g leupeptin/ml, 1 mM phenylmethylsulfonyl fluoride, and 1 mM sodium orthovanadate. Following a 10-min incubation on ice, the lysates were centrifuged at 10,000 rpm for 10 min. Protein concentrations were determined by the method of Bradford and equal amounts of protein were incubated with appropriate antibodies for at least 1 h at 4°C with mixing. Protein A-Sepharose was added (40 l of a 20% solution), and mixing continued for an additional hour at 4°C. Immunoprecipitates were washed three times in lysis buffer containing 0.5% Triton X-100, solubilized into boiling Laemmli sample buffer, subjected to SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to nitrocellulose (Schleicher & Schuell). For Western blotting, membranes were blocked for 1 h in TBST (10 mM Tris-Cl, pH 7.4, 2.5 mM EDTA, 150 mM NaCl, 0.1% Tween 20) containing 3% bovine serum albumin at room temperature and incubated with the appropriate antibody for an additional hour. Immunoreactive bands were detected by enhanced chemiluminescence (Amersham Corp.). For antiphosphotyrosine Western blotting, the membranes were blocked for 1 h as above, followed by the addition of recombinant horseradish peroxidase-conjugated anti-phosphotyrosine Fab fragment, RC20H.
GST Fusion Protein Production-Bacteria expressing full-length GST-Grb2, GST-Syp (SH2-N), and GST-Shc PTB were kindly provided by Drs. Mike Moran, Tony Pawson, and Michel Tremblay, respectively. Fusion proteins were produced by isopropyl-b-D-thiogalactopyranoside induction and purification on glutathione-agarose beads (28) . Approximately 0.5-1.0 g of protein was used in the in vitro association experiments.
Phosphatidylinositol 3Ј Kinase Assays-PI3-kinase assays were performed essentially as described in Ref. 29 . Phosphorylated proteins were immunoprecipitated from cell lysates with an antibody that recognizes phosphorylated tyrosine residues (PY20). Immune complexes were washed as follows: three times in 0.5% Triton X-100 lysis buffer, one time in ice-cold phosphate-buffered saline, one time in 0.5 M LiCl, 0.1 M Tris-Cl, pH 7.5, one time in double-distilled H 2 O, one time in 0.1 M NaCl, 1 mM EDTA, 20 mM Tris-Cl, pH 7.5, and one time in 20 mM Tris-Cl, 0.1 M NaCl, 0.5 mM EGTA. The immunoprecipitates were then preincubated in 50 l of the last wash buffer containing 0.2 mg of phosphatidylinositol/ml for 10 min at room temperature. Phosphorylation was initiated by the addition of 20 Ci of [␥-
32 P]ATP, 20 mM MgCl 2 , and 10 M ATP. The reaction mixtures were incubated for 10 min at 20°C and were terminated by the addition of 150 l CHCl 3 /MeOH/HCl (100:200:2) and 100 l CHCl 3 . The organic phase was washed once with 150 l of MeOH/1 N HCl (1:1) and then spotted onto a silica gel 60 TLC plate. Phosphorylated products were separated by TLC in solvent containing CHCl 3 /MeOH/4 M NH 4 OH/double-distilled H 2 O (9:7:2:2.8) for 1 h, at which time they were visualized by autoradiography.
Fos-Luciferase Assays-Luciferase activity was measured essentially as described in Ref. 30 . Human embryonic kidney 293 cells were plated at 2.5 ϫ 10 5 cells/60-mm dish 24 h prior to transient transfection utilizing calcium phosphate coprecipitation. Cells were transfected with CaCl-purified expression constructs encoding the wild-type and mutant Tpr-Met proteins (200 ng); the Fos-Luc target plasmid (1 g) composed of necleotides Ϫ356 to ϩ109 relative to the start site of the c-fos promoter cloned upstream of the luciferase gene (31); 2 and, to control for transfection efficiency, an L7␤Gal reporter plasmid (1 ). 24 h later the transfection solution was removed, and the cells were washed twice with Dulbecco's modified Eagle's medium and then placed in Dulbecco's modified Eagle's medium/0.1% fetal bovine serum for 24 h. Following two washes with ice cold phosphate-buffered saline, the cells were lysed in 100 l of buffer containing 1% Triton X-100, 100 mM KPO 4 , pH 7.8, 1 mM dithiothreitol for 5 min on ice. The lysates were centrifuged at 10,000 rpm for 5 min. Luciferase activity was measured in 20 l of lysate in the presence of 100 l of luciferase assay reagent composed of 20 , is detectably phosphorylated (34) . Consistent with the phosphorylation data, when Tyr 489 is substituted with a Phe residue, the resulting mutant Tpr-Met protein, Y489F, transforms cells at only 20% of the efficiency of the wild-type oncoprotein (23) , whereas a Y482F Tpr-Met mutant protein transforms cells at wild-type levels (34) . However, a double Y482F/Y489F Tpr-Met mutant fails to transform Fr3T3 cells in culture (18, 34) .
To dissect signaling pathways activated by Tpr-Met and required for transformation of Fr3T3 cells, we have characterized the signaling pathways activated in stable Fr3T3 cell lines expressing the highly transforming Y482F and the nontransforming Y482/489F Tpr-Met mutants. In addition, by taking advantage of the observation that the Grb2 adaptor protein has an absolute requirement for an Asn residue in the ϩ2 position downstream from phosphorylated tyrosine residues (35, 36), we generated a Tpr-Met mutant, N491H, containing a substitution of a His residue for the Asn residue at position 491, two amino acids downstream of Tyr 489 . This mutant is expected to selectively lose the ability to associate with the Grb2 adaptor protein. Ecotropic retroviruses, which expressed wild-type, Y489F, and N491H mutant Tpr-Met proteins were generated, and the ability of each mutant to transform Fr3T3 fibroblasts was examined in a focus forming assay. The N491H Tpr-Met mutant transformed cells at approximately 20% of the efficiency of the wild-type Tpr-Met protein, similar to the transforming activity of the Y489F mutant (Table I) . Moreover, in a manner similar to the cells expressing the Y489F mutant (23), cell lines expressing the N491H mutant grew to reduced cell density when compared with cells expressing the wild-type oncoprotein (data not shown).
The N491H Tpr-Met Mutant Fails to Bind Grb2 but Retains the Ability to Associate with PLC␥ and SHPTP2/Syp and to
Activate PI3-kinase-When expressed in stable cell lines, both wild-type (Fig. 1, A and B, lanes 2 and 3) and mutant forms of Tpr-Met proteins (Figs. 1, A and B, lanes 4 -12) were constitutively phosphorylated on tyrosine residues, and each retained autokinase and exogenous kinase activity toward myelin basic protein (data not shown). To determine if, as predicted, the N491H mutant failed to associate with the Grb2 adaptor protein, lysates from stable cell lines expressing either wild-type or the mutant forms of Tpr-Met were incubated with GSTGrb2. The wild-type (Fig. 2A, lane 7) and the highly transforming Y482F Tpr-Met mutant (Fig. 2A, lane 3) proteins associated with GST-Grb2 in vitro, whereas the N491H mutant protein ( Fig. 2A, lane 6) did not. As demonstrated previously for the Y489F mutant (Fig. 2A, lane 4) , the nontransforming Y482F/ Y489F Tpr-Met mutant also failed to associate with the Grb2 adaptor protein in vitro (Fig. 2A, lane 5) . Similarly, when the association between Tpr-Met and Grb2 was examined in vivo in transiently transfected COS-1 cells, both the wild-type and the Y482F Tpr-Met mutant proteins were able to coimmunoprecipitate Grb2 (Fig. 2B, lanes 2 and 4) , whereas Grb2 was not coimmunoprecipitated by the N491H, Y489F, or Y482F/Y489F Tpr-Met mutants (Fig. 2B, lanes 5, 6, and 7) nor by a kinase inactive Tpr-Met mutant (K241A) (10) (Fig. 2B, lane 3) . Thus, as predicted, the N491H mutant was no longer able to associate with the Grb2 adaptor protein in vivo or in vitro.
The consensus binding sites for numerous SH2 domain-containing proteins have been determined using a library of randomized peptides (35, 36 2C , lanes 1, 2, and 5) were able to associate with the GST-Syp fusion protein, whereas the Y489F or the Y482F/Y489F TprMet mutant proteins were not (Fig. 2C, lanes 3 and 4) . Similarly, the wild-type, Y482F, and N491H Tpr-Met mutants (Fig.  2D, lanes 1, 3, and 4) , when expressed in COS-1 cells, coimmunoprecipitated PLC␥, whereas PLC␥ was not detectably coimmunoprecipitated with the Y489F and Y482F/Y489F Tpr-Met mutants (Fig. 2D , lanes 5 and 6) nor with the kinase inactive K241A Tpr-Met mutant (Fig. 2D, lane 2 ). The steady-state level of PI3-kinase activity associated with phosphotyrosine-containing proteins in stable cell lines expressing each of the Tpr-Met proteins was determined by immunoprecipitation with anti-phosphotyrosine antibodies. Stable cell lines expressing the Y489F Tpr-Met mutant retained only 10% of the PI3-kinase activity present in cell lines expressing the wild-type oncoprotein (23) (Fig. 3, compare lanes 3 and  4 with lanes 9 and 10) , similar to the level present in cells expressing the nontransforming Y482F/Y489F Tpr-Met mutant (Fig. 3, lanes 11 and 12) . In contrast, in cell lines expressing the N491H Tpr-Met mutant (Fig. 3, lanes 7 and 8) , PI3-kinase activity remained at 80 -90% of the level detected in the wild-type or the highly transforming Y482F Tpr-Met mutant expressing cells (Fig. 3, lanes 5 and 6) . Thus, cells expressing either the N491H or the Y482F Tpr-Met mutants retained nearly wild-type levels of PI3-kinase activity, whereas those expressing either the Y489F or Y482F/Y489F mutants retained only basal levels of PI3-kinase activity. These data demonstrate that although the association of Tpr-Met with Grb2, PLC␥, and the SHPTP2/Syp tyrosine phosphatase as well as PI3-kinase was dependent upon the presence of Tyr 
The Shc Adaptor Protein Is Phosphorylated and Coupled with Grb2 in Cell Lines Expressing the Weakly Transforming Y489F or N491H Mutants but Not in Cell Lines Expressing the
Nontransforming Y482F/Y489F Mutant-To determine if the various Tpr-Met proteins were able to interact with the Shc adaptor protein, lysates from stable cell lines expressing either wild-type or mutant forms of Tpr-Met were incubated with a GST-Shc PTB fusion protein encoding amino acids 1-209 of Shc. Although the wild-type, Y482F, and N491H Tpr-Met mutants (Fig. 4A, lanes 2, 3, and 5 ) associated with the GST-Shc PTB fusion protein, the Y489F and the Y482F/Y489F Tpr-Met mutant proteins did not (Fig. 4A, lanes 4 and 6) . Thus, the in vitro association between the Shc PTB domain and the Tpr-Met oncoprotein is dependent upon Tyr 489 yet is independent of the Asn residue two amino acids downstream of Tyr 489 . Although the Y489F Tpr-Met mutant was unable to associate in vitro with the Shc PTB domain, we had previously demonstrated that the 52-kDa isoform of Shc was tyrosine phosphorylated and associated with Grb2 in stable cell lines expressing the poorly transforming Y489F Tpr-Met mutant (Fig. 4, B and C, lanes 8 -10) (23) . The 52-kDa Shc adaptor protein was also phosphorylated on tyrosine and coupled with the Grb2 adaptor protein in Fr3T3 fibroblasts expressing the wild-type (23) (Fig. 4, B and C, lanes 2 and 3) and the highly transforming Y482F (Fig. 4, B and C, lanes 4 and 5) , as well as the poorly transforming N491H (Fig. 4, B and C, lanes 6 and 7) Tpr-Met mutants. In contrast, in the parental Fr3T3 fibroblasts or in stable cell lines expressing the nontransforming Y482F/Y489F Tpr-Met mutant, Shc was neither detectably tyrosine phosphorylated (Fig. 4B, lanes 1, 11, and 12) nor associated with Grb2 (Fig. 4C, lanes 1, 11, and 12) . Thus, stable association in vitro between the Shc PTB domain and the Y489F mutant Tpr-Met protein is apparently not required for Shc phosphorylation in stable cell lines expressing the Y489F mutant. Moreover, phosphorylation of Shc and its association with the Grb2 adaptor protein may contribute to the weakly transforming phenotype of the Y489F and N491H mutants; however, this association is not sufficient for efficient cell transformation by the Tpr-Met oncoprotein.
The Shc/Grb2 complex has been shown to activate Ras in several systems (37) (38) (39) (40) . Activation of Ras has been shown to lead to the induction of the c-fos promoter in transient transfection assays (41) . Thus, to examine the ability of mutant Tpr-Met proteins to activate Ras-dependent pathways, expression plasmids for both the wild-type and mutant Tpr-Met proteins were transfected into human embryonic kidney 293 cells and assayed for their ability to increase transcription of the c-fos promoter fused upstream of the luciferase reporter gene (31) . 3 When compared with wild-type Tpr-Met, all of the mutant Tpr-Met proteins were impaired in their ability to activate the c-fos promoter yet showed elevated levels of luciferase activity over background or cells expressing a kinase inactive Tpr-Met mutant (K241A, Table II ). The level of luciferase activity was reduced to 36% that of wild-type Tpr-Met for the nontransforming Y482F/Y489F Tpr-Met mutant, which failed to bind Grb2 and Shc or to induce phosphorylation of Shc; 49% that of wild-type for the poorly transforming Y489F mutant, 1 and 2) or stable cell lines expressing either wild-type (lanes 3 and 4) or the various Tpr-Met mutant proteins (lanes 5-12) . Proteins were immunoprecipitated with antiphosphotyrosine antibodies (PY20) and PI3-kinase activity determined following the addition of [␥-32 P]ATP and phosphatidylinositol. Phosphorylated products were separated by thin layer chromatography on silica gel plates and visualized by autoradiography. wt, wild type. PIP, phosphatidylinositol 3-phosphate. which failed to bind Grb2 and Shc; and 61% that of wild-type for the poorly transforming N491H mutant, which failed to bind Grb2. Thus, whereas all of the transforming Tpr-Met proteins retained the ability to induce Shc phosphorylation when stably expressed in Fr3T3 cells, the mutant Tpr-Met proteins that had lost the ability to bind to Grb2 were more severely impaired in their ability to both transform cells and increase transcription of the c-fos promoter. DISCUSSION Many substrates have been identified that associate with activated receptor tyrosine kinases; however, it is unclear which signaling pathways mediate transformation by the oncogenic variants of these receptors. We hope to gain insight into the general mechanism of cellular transformation by identifying intracellular signaling pathways utilized by the Tpr-Met oncoprotein to transform Fr3T3 fibroblasts.
We have previously demonstrated that Tyr 489 in the carboxyl terminus of Tpr-Met is required for efficient transformation of Fr3T3 fibroblasts (23) and is essential for activation of PI3-kinase and for the association of the Grb2 adaptor protein with Tpr-Met (23) . In this study we have shown that Tyr 489 is also required for association with PLC␥, the SHPTP2/Syp tyrosine phosphatase, and the Shc adaptor protein, (Figs. 2, C and D,  and 4A ). All of these substrate associations remained at nearly wild-type levels when the carboxyl-terminal tyrosine residue, Tyr
482
, was mutated to a phenylalanine residue (Figs. 2-4 in Tpr-Met cell transformation.
The only detectable difference between the nontransforming Y482/Y489F Tpr-Met mutant and the transforming variants of Tpr-Met was the lack of Shc phosphorylation and its association with Grb2 in cell lines expressing the nontransforming Y482F/Y489F Tpr-Met mutant (Fig. 4, B and C) . In contrast, Shc was both tyrosine phosphorylated and associated with Grb2 in cell lines expressing Tpr-Met proteins that retained transforming activity (wild-type, Y482F, Y489F, and N491H (Fig. 4) ). Thus, both Tyr 482 and Tyr 489 are required for the phosphorylation of Shc in Tpr-Met-expressing cells, and the inability of the Y482F/Y489F Tpr-Met mutant to phosphorylate Shc (albeit directly or indirectly) correlates with the inability of this mutant to transform cells.
All of the Tpr-Met proteins that associated with the GST-Shc PTB domain fusion protein in vitro also induced tyrosine phosphorylation of the 52-kDa isoform of Shc when the Tpr-Met proteins were stably expressed in Fr3T3 fibroblasts (Fig. 4, A  and B) . The Shc PTB domain binds to phosphotyrosine residues preceded by the consensus Asn-Xaa 1 -Xaa 2 , where Xaa 1 is often proline (42) (43) (44) . Consistent with this consensus being located upstream of Tyr 489 (N-A-T-*Y) only (and not Tyr 482 (G-E-H-Y)), the poorly transforming Y489F Tpr-Met mutant protein was unable to associate with the GST-Shc PTB fusion protein in vitro. However, the Y489F Tpr-Met mutant was still able to induce tyrosine phosphorylation of Shc in Fr3T3 fibroblasts expressing this mutant (23) (Fig. 4B) , in a manner similar to that of mutant forms of the platelet-derived growth factor and epidermal growth factor receptors, which also fail to bind directly to Shc (45) (46) (47) . Thus, a stable association between the Y489F Tpr-Met mutant and Shc appears not to be crucial for Shc phosphorylation in vivo.
It was also possible that Shc was acting as an adaptor molecule linking Grb2 to Tpr-Met indirectly as has been suggested for the epidermal growth factor receptor (42, 48) . However, the N491H mutant, which associated with the GST-Shc PTB fusion protein to wild-type levels in vitro (Fig. 4A) , did not detectably associate with Grb2 in vitro or in vivo, demonstrating that a ternary complex between the N491H mutant Tpr-Met protein, Shc, and Grb2 is not abundant and therefore unlikely to play a significant role in the transformation of Fr3T3 fibroblasts by (55) . Cell transformation is strictly dependent upon tyrosine phosphorylation of Shc at position 317 and subsequent association with Grb2 (56) , and where studied, this association correlates with the activation of Ras (38 -40) . Consistent with Shc playing a role in cell transformation, its phosphorylation and association with Grb2 correlates with the partially transformed phenotype of cells expressing Tpr-Met mutant proteins, which fail to associate with Grb2 (Y489F and N491H, Fig. 4) . However, the fact that both of these mutants transform cells at 20% of the efficiency of the wild-type Tpr-Met oncoprotein demonstrates that 1) the association between Shc and the N491H mutant apparently does not contribute significantly to the transformation efficiency of this mutant in the absence of direct Grb2 binding and 2) Shc phosphorylation and association with Grb2 are not sufficient for a fully transformed phenotype (Table I) .
The N491H Tpr-Met mutant, which failed to bind Grb2 (Fig.  2, A and B) , retained the ability to associate with PLC␥, SHPTP2/Syp (Fig. 2, C and D) , and Shc (Fig. 4A) and to activate PI3-kinase in vivo (Fig. 3 ), yet it transformed cells at 20% the efficiency of wild-type Tpr-Met, the same efficiency as that of the Y489F Tpr-Met mutant (Table I) . Therefore, in the absence of direct Grb2 association, activation of pathways downstream of PLC␥, SHPTP2/Syp, and PI3-kinase are insufficient for transformation of Fr3T3 fibroblasts by Tpr-Met.
Grb2 and its homologues, Sem5 and Drk, associate with Sos, a guanine nucleotide exchange factor for Ras (37, (57) (58) (59) , and have been shown genetically to function in pathways containing receptor tyrosine kinases and Ras proteins (60 -62) . Ras activity is required for cell transformation by many oncoproteins (63) and coexpression of a dominant negative form of Ras inhibits the growth of Tpr-Met transformed Fr3T3 fibroblasts, 3 suggesting that pathways downstream of Ras are required for transformation by Tpr-Met. Consistent with this, the Tpr-Met oncoprotein activated the c-fos promoter in transient assays (Table II) , and AP1 activity is elevated in Tpr-Met-transformed cells. 4 Moreover, the Tpr-Met mutants that were unable to bind Shc or Grb2 were impaired in their ability to activate the c-fos promoter compared with the wild-type or Y482F Tpr-Met proteins, which bind to both Grb2 and Shc. Although direct Shc binding may contribute to the activation of the c-fos promoter (compare N491H with Y489F, Table II), it does not appear to play a significant role in transformation because both of these mutants transformed cells with the same efficiency. Thus, a direct association between Grb2 and Tpr-Met is required for full activation of Tpr-Met-regulated, Ras-dependent pathways. In the absence of direct Grb2 binding, neither Shc binding nor tyrosine phosphorylation of Shc and the subsequent association with Grb2 are sufficient. Significantly, the ability to activate the c-fos promoter correlates with the ability of the various mutant Tpr-Met proteins to interact with Grb2 and to transform cells.
Our data have shown that although the Tpr-Met oncoprotein interacts with, activates, or phosphorylates at least six distinct signaling pathways (Ref. 23 and data not shown), the activation of PI3-kinase and the association between Tpr-Met and PLC␥, or SHPTP2/Syp are insufficient for transformation of Fr3T3 fibroblasts. In contrast, pathways downstream of Shc and Grb2 are essential for transformation of Fr3T3 fibroblasts by Tpr-Met.
